targeting disease-causing defects of the mitochondrial genome with engineered mitochondrial...

20
Targeting Disease- Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Carlos T. Moraes Esther Lichtenstein Professor in Neurology University of Miami Miller School of Medicine Dept. of Neurology and Cell Biology [email protected]

Upload: hilda-morrison

Post on 19-Dec-2015

222 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

Targeting Disease-Causing Defects of the Mitochondrial Genome with

Engineered Mitochondrial Nucleases

Carlos T. Moraes                             

Esther Lichtenstein Professor in NeurologyUniversity of Miami Miller School of Medicine

Dept. of Neurology and Cell [email protected]

Page 2: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

mtDNA Heteroplasmy is Important in Defining Cellular Health

heteroplasmy homoplasmyhomoplasmy

Page 3: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

Most patients have a mixture of mutated and wild-type mtDNA(mtDNA heteroplasmy)

Page 4: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

HOW CAN WE ALTER mtDNA HETEROPLASMY?

Wild-type Mutated

*

Page 5: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

Mito-RERE

mito-targeting sequence

polyA

RE

Targeting Restriction Endonucleases to the mitochondrial matrix to promote mtDNA double strand breaks (DSB) and

degradation of mtDNA

RE mtDNA

mtDNA

mtDNA

Page 6: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

A mouse model for mtDNA haplotype differential recognition by a mito-RE

BALB/NZB mtDNA heteroplasmic mouse cells

ApaLI Sites in mtDNA

BALB 1

NZB 0

Expression of Mito-ApaLI

ApaLIC8 HA

Page 7: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

Examine tissues after:6 weeks3 months6 months

AAV9-mito-ApaLI-HA

2-3 days old neonates

Uses of Heteroplasmic MiceTargeting Muscle – AAV9

IP or IV InjectionsNZB

Balbc

ApaLIC8 HA

ApaLI

AAV9-Alkalyne Phosphatase

Gastro

cnem

ius

Quadr

iceps

Soleus

Tib.

Ant

.

Gastro

cnem

ius

Quadr

iceps

Soleus

Tib.

Ant

.

ApaLI-HA

MW

AP Mito-ApaLI

Page 8: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

G Q S BI G Q S BI U

AAV9-AP

NZB mtDNA

Balb mtDNA

AAV9-mito-ApaLI-HA

mtDNA heteroplasmy changes 6 weeks after IP injections of AAV-mito-ApaLI-HA

BI=Before Injection (ear biopsy)G=GastrocnemiusQ=QuadricepsS=Soleus

Page 9: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

New Tools for Genome Editing[ZFN, TALEN, CRISPR]

Page 10: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

TAL Effector Domains

Developing DNA-binding motifs

with new specificities

T0

Page 11: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

DNA Binding by TAL Effector Proteins

Structure of a TAL effector protein wrapped around a DNA double helix. Image based on data from Mak et al., Science 2012

Page 12: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

TAL Effector Nucleases (TALEN)

Page 13: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

mitoTALEN to Cleave mtDNA Point Mutations

Page 14: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

mitoTALEN to Cleave mtDNA point mutations

Page 15: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

mtDNA Changes 14 Days after Transfection

Page 16: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

Complex I Activity in mitoTALEN treated Cells

Page 17: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

Mutant mtDNA elimination

Is not “EDITING”

Page 18: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

IMS

matrix

succinate fumarate

Cyt c

The Oxidative Phosphorylation System

Page 19: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

mtDNA: CaucasiannDNA: Japanese

Is incompatibility between nuclear

DNA and mtDNA a health problem?

Page 20: Targeting Disease-Causing Defects of the Mitochondrial Genome with Engineered Mitochondrial Nucleases Targeting Disease-Causing Defects of the Mitochondrial

Kinetics of mtDNA Heteroplasmy Shift

NZB Balbc

ApaLI

ApaLIC8 HA